Biodistribution and individual dosimetry of I-131-labeled Rituximab in relapsed non-Hodgkin's lymphoma

被引：0
|
作者：
Scheidhauer, K
Wolf, I
von Schilling, C
Schmidt, B
Baumgartl, H
Reidel, G
Peschel, C
Schwaiger, M
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany
[2] Tech Univ Munich, Med Klin 3, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS79
引用
收藏
页码：981 / 981
页数：1
相关论文
共 50 条
  • [1] Radioimmunotherapy in relapsed or refractory B-cell non-hodgkin's lymphoma with I-131-labeled chimericanti CD20 C2B8 (I-131 rituximab)
    Kang, H. J.
    Park, Y. H.
    Kim, S.
    Cheon, G. J.
    Choi, C. W.
    Lim, S. M.
    Lee, S. S.
    Na, I. I.
    Ryoo, B. Y.
    Yang, S. H.
    Kim, W. S.
    Kim, K. H.
    Bang, S. M.
    Yuh, Y. J.
    Nam, S. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 108 - 109
  • [2] Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Jacene, Heather
    Crandall, John
    Kasamon, Yvette L.
    Ambinder, Richard F.
    Piantadosi, Steven
    Serena, Donna
    Kasecamp, Wayne
    Wahl, Richard L.
    MOLECULAR IMAGING AND BIOLOGY, 2017, 19 (03) : 429 - 436
  • [3] Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Heather Jacene
    John Crandall
    Yvette L. Kasamon
    Richard F. Ambinder
    Steven Piantadosi
    Donna Serena
    Wayne Kasecamp
    Richard L. Wahl
    Molecular Imaging and Biology, 2017, 19 : 429 - 436
  • [4] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
  • [5] LOCALIZED BETA DOSIMETRY OF I-131-LABELED ANTIBODIES IN FOLLICULAR LYMPHOMA
    HUI, TE
    FISHER, DR
    PRESS, OW
    EARY, JF
    WEINSTEIN, JN
    BADGER, CC
    BERNSTEIN, ID
    MEDICAL PHYSICS, 1992, 19 (01) : 97 - 104
  • [6] Rituximab used in three cases with relapsed non-Hodgkin's lymphoma
    Elli, Murat
    Yilmaz, Sema
    Aydin, Ramazan
    Murat, Sadriye
    Bilgici, Meltem Ceyhan
    Dagdemir, Ayhan
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (03) : 550 - 552
  • [7] Clinical scale preparation and evaluation of 131I-Rituximab for Non-Hodgkin's Lymphoma
    Kameswaran, Mythili
    Vimalnath, K. Viswanathan
    Rajeswari, Ardhi
    Joshi, Prahlad Vasudeo
    Sarma, H. D.
    Samuel, Grace
    RADIOCHIMICA ACTA, 2014, 102 (06) : 553 - 560
  • [8] Safety of 131I-Rituximab Outpatient Radioimmunotherapy of Non-Hodgkin Lymphoma
    Calais, P. J.
    Turner, J. H.
    MEDICAL PHYSICS, 2011, 38 (06)
  • [9] Personalized Dosimetry of 131I-Rituximab Radioimmunotherapy of Non-Hodgkin Lymphoma Defined by Pharmacokinetics in Bone Marrow and Blood
    Boucek, Jan A.
    Turner, J. Harvey
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2014, 29 (01) : 18 - 25
  • [10] Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 82P - 83P
12345